CAR T-Cells and Safety Signals

This episode considers a new treatment for hypertrophic cardiomyopathy, the world’s most common inherited heart condition, which most affected people don’t even realize they have. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400702. 

In the face of a growing childhood obesity epidemic, some parents and clinicians are turning to new tools such as GLP-1 receptor agonists. This episode explores the implications of that trend. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp240070 ... Show More

A new strain of H5N1 influenza is spreading in dairy cows in the United States. Will it cause an epidemic in humans? And what does our public health system need to do in order to be ready if it does? A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJM ... Show More

<p class="MsoNormal"><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Drs. John Sweetenham and Fred Locke discuss the FDA investigation on the risk of cancer from CAR T-cell therapy and share insights on the known number of cases and the potential implic ... Show More

<p>CAR T cells are genetically engineered to express a receptor that recognizes and kills tumor cells. CAR T-cell products are now FDA approved for 6 hematologic malignancies. Author Jennifer N. Brudno, MD, National Cancer Institute, joins JAMA Deputy Editor Mary McGrae McDermott ... Show More

<p class="" style="white-space:pre-wrap;">In this week’s episode, we pause from our discussion about DLBCL to talk about the fundamentals of CAR-T, BiTE and autologous transplants, which will lay the foundation for subsequent discussions about DLBCL. These therapies are the talk ... Show More

<p>In this episode, Dr. Hind Rafei dives into the cutting-edge world of CAR-NK cell therapy and its potential to revolutionize cancer treatment. Unlike their T-cell counterparts, CAR-NK cells promise enhanced safety and innate tumor-killing ability. But what if their power could ... Show More

In Part 1 of this pair of episodes, Drs. Rita Dib and Joseph Sassine provide a background of CAR-T cell therapy (chimeric antigen receptor T cells) and steer you through the complications that might contribute to fever early after CAR-T.Episodes | Consult Notes | Subscribe | Twit ... Show More

This episode highlights articles and commentaries that help expand our understanding of prognostic biomarkers in CLL, learn more about a streamlined analysis of the granulocyte transcriptome in myeloproliferative neoplasms, explore the role of neutrophil extra cellulartraps in ad ... Show More

<p class="" data-rte-preserve-empty="true" style="white-space:pre-wrap;"><strong>This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ... Show More

Send us Fan MailAs a result of the rapid adoption CAR-T therapy for certain lymphoid malignancies and multiple myeloma, of these treatments, CRS and ICANS will become more common in IM wards in the coming years. Take a listen to learn about how to treat this emerging condition. T ... Show More

In this episode:0:46 Borrowing tricks from cancer could help improve immunotherapyT cell based immunotherapies have revolutionised the treatment of certain types of cancer. However these therapies — which involved taking someone’s own T cells and reprogramming them to kill cancer ... Show More